Charles Schwab’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $65.4K | Sell |
80,845
-33,205
| -29% | -$26.9K | ﹤0.01% | 3437 |
|
|
2025
Q1 | $87.6K | Sell |
114,050
-3,150
| -3% | -$2.42K | ﹤0.01% | 3365 |
|
|
2024
Q4 | $149K | Sell |
117,200
-16,049
| -12% | -$20.5K | ﹤0.01% | 3359 |
|
|
2024
Q3 | $276K | Buy |
133,249
+5,216
| +4% | +$10.8K | ﹤0.01% | 3301 |
|
|
2024
Q2 | $488K | Buy |
128,033
+663
| +0.5% | +$2.53K | ﹤0.01% | 3205 |
|
|
2024
Q1 | $604K | Buy |
127,370
+2,670
| +2% | +$12.7K | ﹤0.01% | 2955 |
|
|
2023
Q4 | $532K | Buy |
124,700
+1,669
| +1% | +$7.13K | ﹤0.01% | 3058 |
|
|
2023
Q3 | $380K | Buy |
123,031
+37,238
| +43% | +$115K | ﹤0.01% | 3147 |
|
|
2023
Q2 | $386K | Buy |
85,793
+22,942
| +37% | +$103K | ﹤0.01% | 3164 |
|
|
2023
Q1 | $358K | Sell |
62,851
-870
| -1% | -$4.96K | ﹤0.01% | 3048 |
|
|
2022
Q4 | $385K | Buy |
63,721
+9,669
| +18% | +$58.4K | ﹤0.01% | 3061 |
|
|
2022
Q3 | $358K | Sell |
54,052
-9,148
| -14% | -$60.6K | ﹤0.01% | 3086 |
|
|
2022
Q2 | $330K | Sell |
63,200
-12,730
| -17% | -$66.5K | ﹤0.01% | 3177 |
|
|
2022
Q1 | $524K | Sell |
75,930
-9,207
| -11% | -$63.5K | ﹤0.01% | 3088 |
|
|
2021
Q4 | $1.06M | Buy |
85,137
+1,152
| +1% | +$14.3K | ﹤0.01% | 2887 |
|
|
2021
Q3 | $2.63M | Buy |
83,985
+11,362
| +16% | +$355K | ﹤0.01% | 2635 |
|
|
2021
Q2 | $2.08M | Sell |
72,623
-2,045
| -3% | -$58.6K | ﹤0.01% | 2705 |
|
|
2021
Q1 | $3.24M | Buy |
74,668
+6,100
| +9% | +$264K | ﹤0.01% | 2501 |
|
|
2020
Q4 | $4.91M | Buy |
+68,568
| New | +$4.91M | ﹤0.01% | 2229 |
|